science wire

« BACK

Pharmacology



Results 2401 - 2450 of 2528.
« Previous 1 ... 45 46 47 48 49 50 ... 51 Next »


Pharmacology - Health - 23.03.2011
FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD
US Food and Drug Administration (FDA) extends review period for new drug application (NDA) by three months to July 2011 Additional time requested to complete review of the large amount of data from c

Economics / Business - Pharmacology - 22.03.2011
Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China
Novartis acquires 85 percent stake in Tianyuan, one of the largest privately held vaccines companies in China Novartis to collaborate with Tianyuan on strengthening its existing product portfolio and

Pharmacology - Health - 21.03.2011
Novartis receives European Commission approval for Gilenya , the first oral multiple sclerosis treatment for use in the EU
Gilenya approved in the EU for people with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS Gilenya showed superior efficacy to interferon beta-1a IM, a commonly prescribed treatment, reducing relapses by 52% (p<0.001) at one year Two-year, placebo-controlled study demonstrated that Gilenya significantly reduced the risk of disability pr

Health - Pharmacology - 18.03.2011
Novartis gains positive CHMP opinion for Lucentis (ranibizumab) to treat vision loss due to macular edema secondary to RVO
Lucentis recommended for approval in EU for visual impairment due to macular edema secondary to branch- and central-retinal vein occlusion (RVO) Pivotal data show rapid and significant improvements i

Pharmacology - Health - 15.03.2011
Second Phase III study of Novartis JAK inhibitor INC424 meets primary endpoint in patients with myelofibrosis
COMFORT-II data show INC424 provides marked clinical improvement in patients with myelofibrosis, measured by reduction in spleen size at 48 weeks compared to best available therapy Myelofibrosis is a

Pharmacology - Health - 09.03.2011
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
Phase III program demonstrated significant improvement in lung function lasting for 24 hours and supported safety and tolerability profile of QAB149 COPD is a progressive and life-threatening lung di

Health - Pharmacology - 09.03.2011
The basic structures of sight deciphered
The basic structures of sight deciphered
Researchers reveal in detail what is happening in the retina during the process of sight During the process of sight, light passes into the eye and triggers a whole series of chemical reactions. At the end of this process, a nerve pulse is generated that carries the visual information to the brain. At the beginning of the process, the light interacts with a protein molecule called Rhodopsin.

Health - Pharmacology - 18.02.2011
Novartis gains positive CHMP opinion for Rasilamlo(TM), a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Rasilamlo combines in a single pill the only approved direct renin inhibitor, Rasilez, with the widely used calcium channel blocker amlodipine Data from over 5,000 mild-to-severe high blood pressure

Economics / Business - Pharmacology - 17.02.2011
Novartis appoints Naomi Kelman as new Head of the Novartis OTC division
Novartis OTC (Over-the-Counter) to become separate division in the group's diversified healthcare portfolio with Kelman reporting to Joseph Jimenez, CEO of Novartis Basel , February 17, 2011 - Novart

Pharmacology - Health - 10.02.2011
Onbrez Breezhaler plus tiotropium provided greater increase in lung function than tiotropium alone
Two Phase III studies demonstrated efficacy benefits of combining once-daily Onbrez Breezhaler 150 mcg with tiotropium in patients with COPD , INTRUST 1 and 2 studies add to comprehensive data supporting Onbrez Breezhaler as effective treatment for COPD with good safety profile Results to be presented at ATS congress in May, 2011 Basel, February 10, 2011 - Novartis has announced that two Phase III studies show that patients with chronic obstruct

Health - Pharmacology - 09.02.2011
Novartis drug Afinitor extends progression-free survival in patients with advanced pancreatic NET, study published in NEJM shows
RADIANT-3 trial shows everolimus more than doubled median progression-free survival from 4.6 to 11.0 months versus placebo No tumor growth after 18 months in 34% of the patients treated

Health - Pharmacology - 08.02.2011
Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer
Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived significantly longer without their disease getting worse Roche announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

Pharmacology - Health - 31.01.2011
FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo , for use in children from 2 years of age
Expanded age indication of Menveo offers new option to help protect young children from 2 to 10 years of age against potentially devastating meningococcal disease Novartis to resubmit Menveo infant i

Economics / Business - Pharmacology - 24.01.2011
Novartis announces agreement to acquire Genoptix, Inc. in all cash offer
Novartis to acquire Genoptix through an all cash tender offer at USD 25.00 per share Genoptix laboratory service offerings provide strategic fit with the current portfolio of companion diagnos

Health - Pharmacology - 24.01.2011
Novartis gains approval for Gilenya as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Gilenya offers an alternative to frequent injections, which is a major advance for people with relapsing-remitting multiple sclerosis in Switzerland and Australia Gilenya showed enhanced efficacy to interferon beta-1a IM, a commonly prescribed treatment, reducing relapses by 52% (p<0.001) at one year Two-year, placebo-controlled study demonstrated that Gilenya significantly reduced the risk of disability progression Basel, January 24,

Pharmacology - Health - 21.01.2011
Novartis gains positive CHMP opinion for Gilenya , first oral multiple sclerosis treatment recommended for approval in the European Union
Gilenya recommended in the EU for people with highly active relapsing-remitting MS despite treatment with beta interferon, or in patients with rapidly evolving severe relapsing-remitting MS Gilenya showed superior efficacy to interferon beta-1a IM, a commonly prescribed treatment, reducing relapses by 52% (p<0.001) at one year Two-year, placebo-controlled study demonstrated that Gilenya significantly reduced the risk of disability prog

Pharmacology - Health - 10.01.2011
Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab
Start of phase II clinical study in patients for Sandoz biosimilar rituximab (Roche's Rituxan / Mabthera ) Sandoz already has robust, high-yield in-house production process Milestone reinforces Sando

Pharmacology - Health - 07.01.2011
Novartis gains new indication for Lucentis in EU for vision loss due to Diabetic Macular Edema, a leading cause of blindness
Lucentis (ranibizumab) is the first licensed therapy to improve vision and vision-related quality of life in patients with visual impairment due to diabetic macular edema (DME) Pivotal data showed Lu

Pharmacology - Health - 05.01.2011
FDA grants supplemental approval for ACTEMRA
Basel, 05 January 2011 FDA grants supplemental approval for ACTEMRA ACTEMRA now includes labeling for the inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in rheumatoid arthritis Roche today announced that the United States (U.S.

Pharmacology - Health - 23.12.2010
European Commission approves Novartis drug Tasigna for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
European Commission approves Novartis drug Tasigna for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia Pivotal Phase III data show superiority over standard of care Glivec in

Pharmacology - Health - 21.12.2010
Novartis drug Tasigna approved in Japan for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
Novartis drug Tasigna approved in Japan for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia Approval based on Phase III trial showing superiority of Tasigna to standard of car

Pharmacology - Health - 20.12.2010
Novartis investigational JAK inhibitor INC424 data met primary endpoint in Phase III trial of patients with myelofibrosis
Novartis investigational JAK inhibitor INC424 data met primary endpoint in Phase III trial of patients with myelofibrosis COMFORT-I trial shows INC424 provides significant clinical improvement in patients with myelofibrosis as measured by spleen size reduction High unmet medical need exists for patients with myelofibrosis, an uncommon and debilitating blood cancer Full results to be submitted for presentation at upcoming medical congress; worldw

Pharmacology - Health - 20.12.2010
Novartis affirms commitment to Russia through USD 500 million multi-year healthcare investment
Novartis affirms commitment to Russia through USD 500 million multi-year healthcare investment Novartis signs Memorandum of Understanding (MoU) with City of St. Petersburg for construction of

Health - Pharmacology - 16.12.2010
EMA/European Committee for Medicinal Products for Human Use (CHMP) update:
Basel, 16 December 2010 Roche provides update on Avastin for metastatic breast cancer following reviews in Europe and the United States Roche confirmed that following the reviews of Avastin (bevacizu

Economics / Business - Pharmacology - 15.12.2010
Novartis to become global leader in eye care, with agreement of 100% merger with Alcon
Novartis to become global leader in eye care, with agreement of 100% merger with Alcon Novartis Board of Directors unanimously approves merger for a value of USD 168 per Alcon share totaling USD 12&p

Health - Pharmacology - 09.12.2010
Study of Novartis drug Zometa for potential new use in early breast cancer did not meet primary endpoint in overall study population
Study of Novartis drug Zometa for potential new use in early breast cancer did not meet primary endpoint in overall study population Interim results of AZURE trial report Zometa added to standard adjuvant therapy did not show disease free survival advantage compared to standard therapy alone In subgroup of women with well-established menopause, an improvement in disease free survival and overall survival was shown in Zometa arm Current applicati

Health - Pharmacology - 09.12.2010
Novartis drug Afinitor plus hormonal therapy delays disease progression in advanced metastatic breast cancer patients
Study shows Novartis drug Afinitor plus hormonal therapy delays disease progression in advanced metastatic breast cancer patients Randomized Phase II study shows 61% of advanced breast cancer patients on everolimus plus tamoxifen had no tumor progression at six months vs.

Pharmacology - Health - 09.12.2010
Roche provides update on leading late-stage pharmaceutical pipeline
Basel and London, 9 December 2010 Roche provides update on leading late-stage pharmaceutical pipeline New data on medicines with the potential to redefine standard of care highlighted at Investor event Roche today will provide an update on its leading late-stage pipeline comprising twelve new molecular entities in key therapeutic areas.

Pharmacology - Health - 06.12.2010
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients LBH589 (panobinostat) shows sustained anticancer activity in Hodgkin lymphoma patients who relapse or are refractory after autologous stem cell transplant High unmet treatment need exists for patients who relapse or become refractory after initial treatment; patients are often in their mid-thirties or younger Bas

Pharmacology - Health - 06.12.2010
Longer-term Phase III data show Novartis drug Tasigna continues to surpass Glivec in slowing disease progression in patients with newly diagnosed CML
Longer-term Phase III data show Novartis drug Tasigna continues to surpass Glivec in slowing disease progression in patients with newly diagnosed CML Fewer patients taking Tasigna for Philadelphia ch

Pharmacology - Health - 04.12.2010
Phase III data published in Lancet show Novartis drug Zometa improves overall survival in newly diagnosed multiple myeloma patients
Phase III data published in Lancet show Novartis drug Zometa improves overall survival in newly diagnosed multiple myeloma patients This press release is not intended for United Kingdom news media Regimen including Zometa significantly improved both progression-free survival and overall survival when compared to regimen including oral clodronate Zometa provided significant clinical anticancer benefit independent of and in addition to significant

Health - Pharmacology - 01.12.2010
Data at ASH, SABCS demonstrate commitment of Novartis R&D in advancing treatments for patients with cancer and rare diseases
Data at ASH, SABCS demonstrate commitment of Novartis R&D in advancing treatments for patients with cancer and rare diseases 24-month update on Phase III data comparing Tasigna to Glivec in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase Afinitor plus hormonal therapy studied in patients with ER+/HER2- metastatic breast cancer with prior exposure to aromatase inhibitors Zometa studies continue to explore anticance

Pharmacology - Health - 11.11.2010
Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development
Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development Interim results from Phase III trial show ASA404 failed to meet primary endpoint of extending survival for the second-line treatment of non-small cell lung cancer Related impairment charges of approximately USD 120 million to be taken in fourth quarter 2010 Basel, November 11, 2010 - Novartis announced today that the

Health - Pharmacology - 04.11.2010
Potential for Novartis Meningitis B vaccine
New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate to cover majority of diverse meningococcal serogroup B strains Data show that antibodies induced by Novartis 4CMenB candidate killed 85 percent of a large collection of MenB strains in adults and 74 percent in infants , who are at highest risk for meningococcal disease Findings highlight the benefit of a multi-component MenB vaccine to provide broad coverage against div

Health - Pharmacology - 03.11.2010
Study shows drug Afinitor reduces size of SEGAs
Subependymal giant cell astrocytoma (SEGA) is a benign brain tumor found in children and adults with tuberous sclerosis (TS) that can cause severe brain swellin. These data previously reported at ASCO show nearly one-third of the 28 patients studied had a reduction of 50% or greater in the size of their largest SEGA.Additional study findings showed treatment with everolimus resulted in a clinically relevant reduction in overall frequency of seizures, which are associated with TS.

Pharmacology - Health - 03.11.2010
Onbrez Breezhaler from Novartis provides greater clinical benefits than tiotropium in new study of COPD patients
Onbrez Breezhaler from Novartis provides greater clinical benefits than tiotropium in new study of COPD patients Study shows Onbrez Breezhaler superior to tiotropium in reducing breathlessness and use of rescue medication and in improving overall health status INTENSITY is first blinded head-to-head study with primary goal of comparing once-daily Onbrez Breezhaler with tiotropium, an established COPD therapy Study shows once-daily Onbrez Breezha

Health - Pharmacology - 30.10.2010
Novartis drug Afinitor approved by FDA as first medication for children and adults with a benign brain tumor associated with tuberous sclerosis
Novartis drug Afinitor approved by FDA as first medication for children and adults with a benign brain tumor associated with tuberous sclerosis Subependymal giant cell astrocytoma (SEGA) is a benign

Health - Pharmacology - 25.10.2010
Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants
Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants New pivotal phase III data show Menveo induced immune responses in a high percentage of infants against four important meningococcal disease-causing serogroups The highest rates of meningococcal disease, a sudden, serious and often deadly disease, occur early in the first year of life Menveo has the potential to be the first meningococcal

Pharmacology - Health - 22.10.2010
Lucentis recommended for approval in EU
Novartis therapy Lucentis recommended for approval in EU to treat patients with vision loss due to Diabetic Macular Edema, a serious complication of diabetes CHMP positive opinion supports Lucentis approval in EU for treatment in patients with visual impairment due to diabetic macular edema (DME) Pivotal data shows Lucentis provided rapid, superior and sustained vision gains compared to the current standard of care Diabetes-associated eye diseas

Health - Pharmacology - 22.10.2010
Novartis Phase III study indicates MF59 adjuvanted influenza vaccine, Fluad , is 75 percent more efficacious than studied non-adjuvanted vaccines in young children
Novartis Phase III study indicates MF59 adjuvanted influenza vaccine, Fluad , is 75 percent more efficacious than studied non-adjuvanted vaccines in young children Phase III results demonstrate 89 percent efficacy of Fluad (vs.

Pharmacology - Health - 16.10.2010
Long-term data show Novartis once-yearly Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis
Long-term data show Novartis once-yearly Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis Aclasta reduced the risk of new spine fractures by 52% over six years versus patients who stopped treatment after three years New data from six-year study validate Aclasta safety profile and support long-term use of annual infusions in patients with postmenopausal osteoporosis More than one million Aclasta infusion

Pharmacology - Health - 12.10.2010
Novartis affirms commitment to sustain efforts toward final elimination of leprosy in partnership with World Health Organization
Novartis affirms commitment to sustain efforts toward final elimination of leprosy in partnership with World Health Organization Novartis signs Memorandum of Understanding with the World Health Org

Health - Pharmacology - 11.10.2010
Phase III Novartis data show potential benefit of Afinitor plus Sandostatin LAR in patients with advanced neuroendocrine tumors
Phase III Novartis data show potential benefit of Afinitor plus Sandostatin LAR in patients with advanced neuroendocrine tumors Everolimus plus octreotide LAR extended time without tumor growth from

Pharmacology - Health - 05.10.2010
Novartis discontinues development of two investigational compounds reflecting enhanced focus on portfolio prioritization and productivity
Novartis discontinues development of two investigational compounds reflecting enhanced focus on portfolio prioritization and productivity Human Genome Sciences and Novartis to stop further developmen

Pharmacology - Economics / Business - 30.09.2010
Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney’s Office
Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney's Office Novartis Pharmaceuticals Corporation reaches resolution with US Attorney's

Health - Pharmacology - 24.09.2010
Novartis drug Tasigna recommended for approval in European Union to treat patients with newly diagnosed Ph+ chronic myeloid leukemia
Novartis drug Tasigna recommended for approval in European Union to treat patients with newly diagnosed Ph+ chronic myeloid leukemia Positive CHMP opinion based on pivotal trial showing Tasigna super

Health - Pharmacology - 24.09.2010
Novartis receives EU approval recommendation for TOBI Podhaler , a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients
Novartis receives EU approval recommendation for TOBI Podhaler , a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients CHMP supports approval of TOBI Podhaler, a new dry powder form of tobramycin for treating chronic P. aeruginosa lung infection in cystic fibrosis patients over six Data show new formulation reduces administration time by 72% compared to TOBI, with same efficacy and using more convenient
« Previous 1 ... 45 46 47 48 49 50 ... 51 Next »